May 09, 2019 / 08:00AM GMT
Ãystein Soug - Targovax ASA - CEO
Ladies and gentlemen, welcome to this quarterly presentation of Targovax. Welcome to the people in the room. Welcome to people on the web. My name is Ãystein Soug, and with me today, I have our CFO, Torbjørn Furuseth.
I suspect that most of the people listening into this, they are familiar with our technology. But for the benefit of those who are not too familiar, I will give you a short introduction to who we are and what we are doing.
And what you see on this slide is an overview of the cancer therapy landscape, the way we picture it today. It's a map of what's happening in cancer treatment. And of course, still, surgery, radiotherapy and chemotherapy plays a very central role in treating cancer patients. But immunotherapies are getting an increased usage all around the world. And particularly checkpoint inhibitors, immune modulators, they are proven to be very important in the cancer treatment. Many patients today rely on checkpoint inhibitors in their treatment. And not only is it a good thing for the patients, it's also
Q1 2019 Targovax ASA Earnings Call Transcript
May 09, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers